United Bank Kazia Therapeutics LTD Transaction History

United Bank

  • $820 Million
  • Q2 2025

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024
BUY
$0.19 - $1.24 $8,360 - $54,560
44,000 New
44,000 $18,000

Others Institutions Holding KZIA

# of Institutions
1
Shares Held
125
Call Options Held
0
Put Options Held
0
View Full List

About KAZIA THERAPEUTICS LTD

KZIA Quotes by TradingView
  • Ticker KZIA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 15,111,300
  • Market Cap $136M
  • Description
  • Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various...
More about KZIA
Track This Portfolio

Track United Bank Portfolio

Follow United Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of United Bank, based on Form 13F filings with the SEC.

News

Stay updated on United Bank with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email